1121-46-6Relevant articles and documents
Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase
López-Rodríguez, María L.,Viso, Alma,Ortega-Gutiérrez, Silvia,Fowler, Christopher J.,Tiger, Gunnar,De Lago, Eva,Fernández-Ruiz, Javier,Ramos, José A.
, p. 1512 - 1522 (2003)
A new series of arachidonic acid derivatives were synthesized and evaluated as inhibitors of the endocannabinoid uptake. Most of them are able to inhibit anandamide uptake with IC50 values in the low micromolar range (IC50 = 0.8-24 μM). ln general, the compounds had only weak effects upon CB1, CB2, and VR1 receptors (Ki > 1000-10000 nM). In addition, there was no obvious relationship between the abilities of the compounds to affect anandamide uptake and to inhibit anandamide metabolism by fatty acid amidohydrolase (FAAH; IC50 = 30-113 μM). This indicates that the compounds do not exert their effects secondarily to FAAH inhibition. It is hoped that these compounds, particularly the most potent in this series (compound 5, UCM707, with IC50 values for anandamide uptake and FAAH of 0.8 and 30 μM, respectively), will provide useful tools for the elucidation of the role of the anandamide transporter system in vivo.
-
Herz,Tocker
, p. 3554 (1955)
-
Condensed polycyclic pyridone derivative and application thereof
-
, (2021/06/06)
The invention belongs to the field of medicines, and particularly relates to a fused polycyclic pyridone derivative as shown in a formula I, pharmaceutically acceptable salts, solvates, including hydrates, polycrystals, prodrugs, eutectics, tautomers and stereoisomers thereof, and application of the fused polycyclic pyridone derivative and the pharmaceutically acceptable salts, the solvates, the tautomers and the stereoisomers. Particularly, the compound provided by the invention can be used as an anti-influenza drug with a CEN inhibition effect.
LIVER X RECEPTORS (LXR) MODULATORS
-
, (2018/11/22)
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXR?) and act preferably as inverse agonists of LXR.
ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME
-
, (2017/07/26)
Organic metal compounds, and organic light-emitting devices employing the same are provided. The organic metal compound has a chemical structure represented by formula (I): wherein each R1 is independent and can be hydrogen, C1-12 al